Singapore Approves New Pneumonia Vaccine for Adults

Published 2026-10-29

Singapore's Health Sciences Authority (HSA) has approved CAPVAXIVE, a new pneumococcal vaccine made by MSD. The vaccine is designed to protect adults against invasive pneumococcal disease and pneumococcal pneumonia. Pneumococcal bacteria can cause serious illnesses, including blood infections, meningitis, and severe lung infections, so the approval gives adults in Singapore another option for protection.

CAPVAXIVE is a pneumococcal conjugate vaccine that works against 21 different types, or serotypes, of the bacteria. Vaccines of this kind help the body's immune system recognise and fight the bacteria before they cause serious disease. Because the bacteria come in many different types, a vaccine that covers more types can offer broader protection than older vaccines.

The approval means that the vaccine can now be used in Singapore for adults who are at risk of these infections. Older adults and people with certain long-term health conditions are often more vulnerable to pneumococcal disease. Adults who are thinking about vaccination are advised to speak with a doctor or healthcare provider to find out whether the vaccine is suitable for them.

Health authorities note that vaccination is one of several ways to reduce the risk of pneumococcal infections. Regular check-ups and good hygiene, such as frequent handwashing, also help to prevent the spread of respiratory illnesses. More information about the vaccine and its availability is expected to be shared by healthcare providers in the coming months.

Sources: BioSpectrum Asia

More Singapore news

All Singapore news · News by country